企業プロフィール
Atara Biotherapeutics, Inc. 株価・ニュース・カタリスト
- ティッカー:
- ATRA
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
8.36 USD (+3.34%)
終値
最終更新: 2026年8月17日
89.2M USD
時価総額
株価変動の要因
As of Aug 17, 2026, ATRA closed up 3.34% at $8.36. No new same-company headline was identified in the current news window.
企業概要
Allogeneic EBV T-Cell Platform
Atara Biotherapeutics develops off-the-shelf T-cell therapies generated from healthy donors and directed against Epstein-Barr virus antigens. Its platform does not require T-cell-receptor or HLA gene editing.
Tabelecleucel
Tabelecleucel, also known as tab-cel or EBVALLO, is an allogeneic EBV-specific T-cell therapy for Epstein-Barr virus-positive post-transplant lymphoproliferative disease. The U.S. application is supported by the pivotal single-arm ALLELE study.
Partnered Regulatory Model
Pierre Fabre Pharmaceuticals controls the U.S. regulatory and commercial program. Atara supports the BLA resubmission and retains eligibility for an approval milestone, commercial milestones, and tiered royalties.
今後のカタリスト
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。